A Phase I, Dose-Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas
Study of CS5001 in Patients with Advanced Solid Tumors
Sponsor: CStone
Enrolling: Male and Female Patients
IRB Number: AAAU0306
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is a study of the experimental drug CS5001 developed by CStone pharmaceutical, in patients with advanced hematological and solid tumors. CS5001 will target certain receptors that are in high levels on cancer cells. This study will look at the anti-tumor activity of CS5001. CS5001 is not approved by any regulatory agency for the treatment of any condition. It is only available in clinical studies such as this one. To date, it has only been tested in animal studies. This is the first time that the study drug will be given to humans. Cancers include bladder cancer, breast cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers, head and neck/oral cancer, kidney cancer, leukemia, liver cancer, lung cancer, pancreatic cancer, prostate cancer, stomach cancer, testicular cancer, and thyroid cancer.
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have advanced solid tumors? Yes No
Are you willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162